Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2023 08:30 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
March 07, 2023 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20...
March 01, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
February 22, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
February 21, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

WARREN, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
January 06, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for...
December 22, 2022 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studiesFDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance...
November 29, 2022 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

WARREN, N.J., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through...
November 15, 2022 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through...
November 09, 2022 16:33 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through...